(Q44951728)

English

Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2

object named as

Hans D Ochs

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Emma Guttman-Yassky

5

object named as

Emma Guttman-Yassky

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

James G. Krueger

1

object named as

James G Krueger

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Piyush Patel

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ellen Gilkerson

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Wolfgang Dummer

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

22 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Journal of Investigative Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

128

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2615-2624

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

https://scigraph.springernature.com/pub.10.1038/jid.2008.98

0 references

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour-necrosis-factor antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of antibody responses: the role of complement and adhesion molecules

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Human antibody responses to bacteriophage phi X 174: sequential induction of IgM and IgG subclass antibody

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged inhibition of an antigen-specific IgE response in vivo by monoclonal antibody against lymphocyte function-associated antigen-1

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antiviral antibody responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/JID.2008.98

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44951728&oldid=2059220328"